Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project

Background: Available real-world data on the efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) in pediatric patients are limited. In this prospective, open-label, single-center study, we aimed to present our real-life experience with a fixed dose of LDV/SOF (90/400 mg) for the treatment of chro...

Descripción completa

Detalles Bibliográficos
Autores principales: Pokorska-Śpiewak, Maria, Dobrzeniecka, Anna, Aniszewska, Małgorzata, Marczyńska, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465669/
https://www.ncbi.nlm.nih.gov/pubmed/34575286
http://dx.doi.org/10.3390/jcm10184176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465669/
https://www.ncbi.nlm.nih.gov/pubmed/34575286
http://dx.doi.org/10.3390/jcm10184176

Ejemplares similares